newsfilter
← Latest News
GlobeNewswire·

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of